top of page

Rubix LS in the Boston Business Journal

After over a year of helping pharmaceutical companies reach underrepresented patients through its data analytics platform, Lawrence startup Rubix Life Sciences is getting into therapeutics itself.

This summer, Rubix announced a new therapeutics division with plans to focus on neurodegenerative and infectious diseases. Now, it’s building out a 40,000-square-foot clinical trials site to support those operations.

The article and its contents can be found following this link Rubix LS & Therapeutics Launch into Health Equity

bottom of page